Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Vitiligo is a chronic skin depigmentation disorder affecting 0.5% of the population.
• Recent international consensus revised nomenclature, establishing vitiligo as an umbrella term for generalized forms.
• Differential diagnosis from other hypopigmented disorders is crucial, sometimes requiring skin biopsy.

Purpose of the Study:

• To review the classification, clinical aspects, and pathophysiology of vitiligo.
• To emphasize the role of immunopathogenesis in vitiligo development.
• To explore promising innovative therapeutic strategies based on recent advancements.

Main Methods:

• Literature review focusing on classification, clinical presentation, and pathophysiology.
• Analysis of genetic, environmental, metabolic, and immune factors contributing to melanocyte loss.
• Examination of current research on immunopathogenesis, including genome-wide association studies and immune cell infiltrates.
• Review of emerging therapeutic targets and strategies.

Main Results:

• The autoimmune/inflammatory theory is the leading hypothesis, supported by associations with autoimmune diseases and genetic loci encoding immunomodulatory proteins.
• Evidence also suggests melanocyte intrinsic abnormalities, leading to instability and immune system activation.
• Understanding immune pathomechanisms offers new avenues for innovative treatments, such as targeting the IFNγ/Th1 pathway.

Conclusions:

• Vitiligo pathogenesis involves complex interactions between genetic predisposition, environmental triggers, and immune responses.
• Targeting specific immune pathways, like IFNγ/Th1, and addressing oxidative stress shows promise for future vitiligo therapies.
• Further research into pathomechanisms is essential for developing effective and stabilizing treatments for vitiligo.